Janus Henderson Group PLC Travere Therapeutics, Inc. Transaction History

Janus Henderson Group PLC

$194 Billion
Q2 2025

A detailed history of Janus Henderson Group PLC transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 9,541,270 shares of TVTX stock, worth $166 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares

9,541,270

Previous 7,528,622 26.73%

Holding current value

$166 Million

Previous $135 Million 4.67%

% of portfolio

0.07%

Previous 0.08%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$13.49 - $21.54 $27.2 Million - $43.4 Million	2,012,648 Added 26.73%	9,541,270 $141 Million
Q1 2025 May 15, 2025	BUY	$17.07 - $23.75 $59.2 Million - $82.4 Million	3,469,990 Added 85.5%	7,528,622 $135 Million
Q4 2024 Feb 14, 2025	BUY	$13.65 - $19.85 $55 Million - $79.9 Million	4,026,819 Added 12657.78%	4,058,632 $70.7 Million
Q2 2024 Aug 14, 2024	SELL	$5.26 - $8.28 $1,935 - $3,047	-368 Reduced 1.14%	31,813 $261,000
Q1 2024 May 15, 2024	BUY	$7.18 - $9.82 $7 - $9	1 Added 0.0%	32,181 $248,000
Q4 2023 Feb 14, 2024	SELL	$5.44 - $9.5 $299 - $522	-55 Reduced 0.17%	32,180 $289,000
Q3 2023 Nov 14, 2023	SELL	$7.64 - $17.25 $53 Million - $120 Million	-6,934,735 Reduced 99.54%	32,235 $288,000
Q2 2023 Aug 14, 2023	BUY	$15.3 - $22.61 $1.85 Million - $2.74 Million	121,157 Added 1.77%	6,966,970 $107 Million
Q1 2023 May 15, 2023	BUY	$17.82 - $22.89 $31.3 Million - $40.2 Million	1,754,528 Added 34.46%	6,845,813 $154 Million
Q4 2022 Feb 14, 2023	BUY	$18.47 - $26.14 $21.8 Million - $30.8 Million	1,178,800 Added 30.13%	5,091,285 $107 Million
Q3 2022 Nov 14, 2022	SELL	$22.91 - $28.63 $2.89 Million - $3.61 Million	-126,146 Reduced 3.12%	3,912,485 $96.4 Million
Q2 2022 Aug 15, 2022	SELL	$20.94 - $30.01 $2.37 Million - $3.4 Million	-113,416 Reduced 2.73%	4,038,631 $97.9 Million
Q1 2022 May 16, 2022	BUY	$23.61 - $30.6 $3.21 Million - $4.16 Million	135,889 Added 3.38%	4,152,047 $107 Million
Q4 2021 Feb 14, 2022	SELL	$24.34 - $31.17 $168,335 - $215,571	-6,916 Reduced 0.17%	4,016,158 $125 Million
Q3 2021 Nov 16, 2021	BUY	$12.98 - $25.03 $1.53 Million - $2.95 Million	117,961 Added 3.02%	4,023,074 $97.6 Million
Q2 2021 Aug 16, 2021	SELL	$14.11 - $26.4 $3.46 Million - $6.48 Million	-245,443 Reduced 5.91%	3,905,113 $57 Million
Q1 2021 May 17, 2021	BUY	$23.37 - $31.77 $1.57 Million - $2.13 Million	67,003 Added 1.64%	4,150,556 $104 Million
Q4 2020 Feb 16, 2021	BUY	$19.17 - $27.87 $78.3 Million - $114 Million	4,083,553 New	4,083,553 $111 Million

Others Institutions Holding TVTX

# of Institutions

230

Shares Held

102M

Call Options Held

1.71M

Put Options Held

401K

View Full List

About Travere Therapeutics, Inc.

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.12B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

More about TVTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.

Account

Janus Henderson Group PLC Travere Therapeutics, Inc. Transaction History